---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-062629"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:55:28.903756+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports Q4/FY2024 results, cash $212.5M through 2027; launches $22.35M ATM offering

## Summary
- Entered ATM equity offering of up to $22.35M via Oppenheimer; 3% commission; proceeds to support pipeline.
- Cash, equivalents and marketable securities $212.5M at year-end; expected to fund operations through 2027.
- Net loss $73.9M for FY2024 includes $51.7M in-process R&D from Tenet acquisition; Q4 net loss $8.4M.
- FDA cleared Phase 2 trial for budoprutug in pMN and Phase 1b/2a in ITP; dosing starts H1/H2 2025.
- In-licensed CLYM116 (anti-APRIL) for IgAN; IND-enabling; preclinical data H2 2025; new CBO Perrin Wilson.

## SEC filing metadata
- accession: 0001193125-25-062629
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/0001193125-25-062629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312525062629/d943630d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-062629
- JSON: https://secwatch.observer/filing/0001193125-25-062629.json
- Plain text: https://secwatch.observer/filing/0001193125-25-062629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.